Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has begun recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens. This move signals the company's progress in advancing its technology beyond the initial safety-focused phase and into evaluating vision performance.
The Group Two study will assess both safety and near-and-distance vision performance, unlike Group One which focused solely on safety. Patients in this group will receive the latest-generation Ocumetics Lens, implanted using an enhanced delivery system. The surgeries are targeted for Fall 2026, following the successful completion of Group One surgeries in Fall 2025 at the same Mexico City facility.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about the milestone, stating, "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
This announcement comes as Group One patients approach their 12-month follow-up visits, which will provide longer-term clinical data. The positive outcomes from Group One met and exceeded the company's expectations regarding safety, performance, and handling. "We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens," added Burns. "At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system. This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances."
The significance of this development lies in the potential of the Ocumetics Lens to eliminate the need for corrective lenses by mimicking the eye's natural focusing ability. The lens is designed to fit within the natural lens compartment and utilize the eye's muscle activity to shift focus from distance to near, offering clear vision at all distances without perceptible time lag. If successful, this technology could transform the field of ophthalmology and improve the quality of life for millions of people.
Ocumetics is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is in the first-in-human early feasibility study phase, and the progression to Group Two is a critical step in validating the technology's safety and efficacy. The initiation of patient recruitment underscores the company's commitment to advancing its clinical program and bringing this innovative intraocular lens to market.
As the company moves forward, the ophthalmic community and potential investors will be watching closely for the results from Group Two and the longer-term data from Group One. The outcomes of these studies will be pivotal in determining the future of the Ocumetics Lens and its potential impact on vision correction.
